Ascend Biopharmaceuticals is a company that is developing treatments for metastatic cancers and the cells that promote and influence tumor micro-environments. The company was founded in South Melbourne, Victoria, Australia.
The company's medicines are designed to treat primary and recurrent forms of metastatic cancers. Ascend Biopharmaceuticals uses viral vectors and affinity agents in order to create their small molecule payloads, which they deliver through immune modulators, kinase inhibitors, or chemotherapeutics.
The cells that Ascend's technologies and treatments are designed to destroy grow in tumor environments, and regulate the growth of tumor cells.
Timeline
Patents
Further Resources
Ascend Biopharmaceuticals Announces Encouraging Phase I/IIa Interim Results of ASN-002 Treatment of Nodular Basal Cell Carcinoma (nBCC)
Ascend Biopharmaceuticals Ltd
Web
Transgene Grants Ascend Biopharmaceuticals a License to TG1042, an Immunotherapy to Treat Basal Cell Carcinoma, a Common Type of Skin Cancer
Business Wire
Web